Thank you for Subscribing to CIO Applications Weekly Brief
RealView Imaging Receives FDA Clearance for its Groundbreaking HOLOSCOPE-i Holographic System
The HOLOSCOPETM-i system was built and suited to the specific demands of clinicians and interventionalists, with an "over-the-head" system configuration suspended above the physician, requiring no head-mounted device, special eyewear, or interface tools.
FREMONT, CA: RealView Imaging Ltd. has received FDA 510(k) clearance for its HOLOSCOPE-i holographic system. The system creates spatially accurate, three-dimensional interactive medical holograms based on data received from standard CT scans and 3D ultrasound systems. The HOLOSCOPE-i is the first and only medical holography system to offer physicians a natural 3D visualization experience, allowing direct and precise interaction with dynamic holograms of the patient's true anatomy floating in free space at hand's reach before and during interventional procedures.
The HOLOSCOPETM-i system was built and suited to the specific demands of clinicians and interventionalists, with an "over-the-head" system configuration suspended above the physician, requiring no head-mounted device, special eyewear, or interface tools. The HOLOSCOPETM-i is the only commercial product that uses real interference-based volumetric holography (a Nobel Prize winning technique) to make holograms with great spatial resolution in all three dimensions. It is based on the company's unique Digital Light ShapingTM technology. This distinct technological advantage enables natural 3D/4D visualization and extended system use without causing fatigue, nausea, or headache, which are major issues with all currently available 3D stereoscopic visualization solutions, including Augmented Reality headsets, Virtual Reality headsets, as well as stereoscopic screens.
Earlier this year, the company raised $15 million in a Series C fundraising round. Judith and Kobi Richter, the Lowy Medical Research Institute, OurCrowd VC, Rami Ungar, and Club100Plus Investments Group were among the notable investors in this round. The bulk of the company's current shareholders, including serial technology and medical investors Dr. Shimon Eckhouse and Zohar Gilon, also joined in this round.